EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance

Hideshi Torii iD, Akimichi Morita, Chie Yamamoto, Jiayi Dong, Mika Tsujimoto, Takashi Matsuo iD, Hitoe Torisu-Itakura iD, Mamitaro Ohtsuki iD, Hidehisa Saeki iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Hideshi Torii und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report findings from a post‐marketing study conducted from November 2016 to September 2022, which evaluated the safety and effectiveness of ixekizumab in Japanese patients with psoriasis under routine clinical practice for up to 52 weeks, and the incidence of serious infections and malignancies for up to 3 years. Of 804 patients in this analysis (67.9% male; median age, 54 years; mean disease duration, 11.8 years), 72.9%, 37.7%, 7.8%, and 3.7% had psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis, respectively (subtypes not mutually exclusive). At 52 weeks, adverse events were reported in 203 patients (25.3%). Serious adverse events were reported in 36 patients (4.5%), including serious infections and infestations ( n = 13, 1.6%). The incidence of serious infections and benign, malignant, and unspecified neoplasms was 0.8% ( n = 5) and 0.6% ( n = 4) respectively, at 3 years. Overall, 137 patients (17.0%) received Q2/Q2 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from week 12); 550 patients (68.4%) received Q2/Q4 treatment (160 mg starting dose, followed by 80 mg every 2 weeks from weeks 2 to 12 and 80 mg every 4 weeks thereafter); and 117 patients (14.6%) discontinued before week 12 or received only one dose after week 12. A higher proportion of patients in the Q2/Q2 group had psoriatic arthritis (56.9% [ n = 78]) compared with the Q2/Q4 group (32.9% [ n = 181]). Among patients in the Q2/Q2 versus the Q2/Q4 dose groups, 21 (15.3%) and 141 (25.6%) respectively had adverse events and 2 (1.5%) and 32 (5.8%) respectively had serious adverse events. The mean Psoriasis Area and Severity Index score and body surface area percentage significantly decreased from baseline to week 52 for all psoriasis subtypes and by Q2/Q2 and Q2/Q4 ixekizumab doses ( p < 0.01 or p < 0.001). Overall, the safety and effectiveness of ixekizumab in real‐world settings in Japan were similar to those reported in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleMiddle AgedFemaleProduct Surveillance, PostmarketingAdultJapanTreatment OutcomeAgedIncidenceSeverity of Illness IndexArthritis, PsoriaticNeoplasmsYoung AdultEast Asian People

Stichwörter der Autor:innen

ixekizumabpost‐marketingpsoriasissafetytreatment effectiveness

Substanzen

ixekizumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
  • Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.

ORCID-Profile: Hideshi Torii, Takashi Matsuo, Hitoe Torisu-Itakura, Mamitaro Ohtsuki, Hidehisa Saeki

Zitieren

APA

Torii, H., Morita, A., Yamamoto, C., Dong, J., Tsujimoto, M., Matsuo, T., Torisu-Itakura, H., Ohtsuki, M., & Saeki, H. (2025). Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17695

Vancouver

Torii H, Morita A, Yamamoto C, Dong J, Tsujimoto M, Matsuo T, et al. Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17695

BibTeX
@article{Torii2025,
  author = {Torii, Hideshi and Morita, Akimichi and Yamamoto, Chie and Dong, Jiayi and Tsujimoto, Mika and Matsuo, Takashi and Torisu-Itakura, Hitoe and Ohtsuki, Mamitaro and Saeki, Hidehisa},
  title = {Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17695}
}
Kostenlos starten →